Home » Contract Delays Force Genaissance to Cut 2004 Revenue Outlook by 20 Percent

Contract Delays Force Genaissance to Cut 2004 Revenue Outlook by 20 Percent

Oct 21, 2004

NEW YORK, Oct. 21 (GenomeWeb News) - Genaissance Pharmaceuticals lowered by around 20 percent its year-end revenue expectations, to between $20 million and $21 million from $25 million, the company said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Drive Resistance

Gene drives might run into biological resistance, the Economist reports.

Dalí DNA Collected

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Synthetic-Conservation Biology Disconnect

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

This Week in Science

In Science this week: full CRISPR locus integration complex structure, and more.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.